SummaryWe investigated coagulation system activation following estrogen treatment in 29 healthy postmenopausal women. Study participants received conjugated estrogens at 0.625 and 1.25 mg per day, and placebo for 3-month periods in a randomized crossover protocol. Blood samples were obtained on two consecutive days at the end of each treatment period for immunoassays of F1+2 and fibrinopeptide A (FPA), markers of factor Xa action on prothrombin and thrombin action on fibrinogen in vivo, respectively. Treatment with estrogens at a dose of 0.625 or 1.25 mg resulted in significant increases in mean F1+2 levels of 40 and 98%, respectively, and in mean FPA levels of 37 and 71%, respectively. The measurements of F1+2 were significantly higher in women receiving 1.25 mg of estrogen than 0.625 mg. We also observed significant declines in the levels of antithrombin III and total protein S antigen. Immunologic levels of protein C increased modestly at only the 1.25 mg estrogen dose level. These data indicate that low doses of oral estrogens (≤1.25 mg per day) frequently increase the amount of thrombin generated in vivo. Our observations may help to explain the increased thrombotic risk that has been observed with higher doses of this medication (≥2.5 mg).

No abstract

The effects of low doses of melatonin (0.1, 0.5 and 1 mg) given at 16:00 h on induction and quality of sleep in the late afternoon (17:00-21:00 h), as well as on subjective fatigue and mood ratings before and after sleep were studied. Ten healthy male volunteers (age 26-30 years) were given on a doubleblind crossover basis, tablets containing melatonin, or placebo, with one day washout between treatments. Mood and fatigue were assessed before and after bedtime. Sleep quality was objectively monitored using wrist-worn actigraphs and subjectively by using sleep logs. Data were analysed by means of analysis of variance for repeated measures with a factor of group (placebo and the three melatonin doses).The analysis revealed dose-dependent increase by melatonin in subjective evaluation of fatigue and sleepiness, and decrease in alertness, efficiency, vigor and concentration before the nap. Melatonin did not significantly affect actigraph-measured nap sleep latency and efficiency but reduced wake time after sleep onset and delayed sleep offset time compared to placebo, Melatonin did not significantly affect sleep latency and sleep efficiency in the night following the treatment.These data indicate acute effects of low doses of melatonin given at 16:00h on sleepiness and fatigue but not on sleep efficiency or latency in healthy young individuals.